Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Long-lasting HIV prevention drug could be game changer — but who will pay?

Injectable antiviral cabotegravir provides stronger protection than oral pill, but researchers fear it could be too expensive to make a difference for countries with the greatest disease burden.
  1. T.V. Padma
    View author publications

    You can also search for this author in PubMed  Google Scholar

An injectable drug that protects people at high risk of HIV infection has been recommended for use by the World Health Organization (WHO). Cabotegravir (also known as CAB-LA), which is given every two months, was initially approved by the US Food and Drug Administration in December 2021.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 608, 460-461 (2022)

doi: https://doi.org/10.1038/d41586-022-02123-x

Updates & Corrections

  • Correction 16 August 2022: An earlier version of this article incorrectly stated the full name of Wits Reproductive Health and HIV Institute (Wits RHI).

References

  1. Delany-Moretlwe, S. et al. Lancet 339, 1779–1789 (2022).

    Article  Google Scholar 

  2. Jamieson, L. et al. Preprint at SSRN https://doi.org/10.2139/ssrn.4047136 (2022).

Download references

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links